AIDA Network real-world IL-1 inhibitor data: 60-month retention 64.7%

Calabrese et al. (2025) reported long-term real-world effectiveness of anakinra and canakinumab in 28 SchS patients (37 treatment lines) from the international AIDA Network registry. Complete response rates were 73.1% (anakinra) and 66.8% (canakinumab). Drug retention at 60 months was 64.7%. Elevated IgG M-protein and lymphadenopathy independently predicted treatment discontinuation.